{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:48:32Z","timestamp":1780321712271,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010891","name":"Portola Pharmaceuticals, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010891","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010891","name":"Portola Pharmaceuticals, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010891","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ahj.2016.12.004","type":"journal-article","created":{"date-parts":[[2016,12,18]],"date-time":"2016-12-18T13:50:48Z","timestamp":1482069048000},"page":"93-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial"],"prefix":"10.1016","volume":"185","author":[{"given":"C. Michael","family":"Gibson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rim","family":"Halaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Korjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Daaboul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3510-9706","authenticated-orcid":false,"given":"Douglas F.","family":"Arbetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan K.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Z.","family":"Goldhaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russel","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiao-ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Bandman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet M.","family":"Leeds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2016.12.004_bb0005","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1160\/TH07-03-0212","article-title":"Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality","volume":"98","author":"Cohen","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2016.12.004_bb0010","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ahj.2016.12.004_bb0015","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.ahj.2016.12.004_bb0020","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1056\/NEJMoa1601747","article-title":"Extended thromboprophylaxis with betrixaban in acutely ill medical patients","volume":"375","author":"Cohen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.12.004_bb0025","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ahj.2013.11.006","article-title":"The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study","volume":"167","author":"Cohen","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2016.12.004_bb0030","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ahj.2014.09.004","article-title":"Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment","volume":"169","author":"Cohen","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2016.12.004_bb0035","first-page":"343","article-title":"Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism","volume":"11","author":"Chan","year":"2015","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.ahj.2016.12.004_bb0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH08-07-0460","article-title":"A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)","volume":"101","author":"Turpie","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2016.12.004_bb0045","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/eurheartj\/eht039","article-title":"Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)","volume":"34","author":"Connolly","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2016.12.004_bb0050","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.bmcl.2009.02.111","article-title":"Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenz amide, a highly potent, selective, and orally efficacious factor Xa inhibitor","volume":"19","author":"Zhang","year":"2009","journal-title":"Bioorg Med Chem Lett"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870316302812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870316302812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:57:41Z","timestamp":1757570261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870316302812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":10,"alternative-id":["S0002870316302812"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2016.12.004","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2016.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}